Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, is seeking to raise $212.4 million in a US initial public offering.
About
Charles Delingpole is a serial entrepreneur and technology leader with extensive experience in fintech, insurtech, and digital innovation.
Background
- Founder and Executive Chairman of ComplyAdvantage, a leading RegTech company providing AI-driven compliance solutions
- Previously founded MarketInvoice (now MarketFinance/Kriya), a pioneering invoice finance platform
- Former JPMorgan banker specializing in technology, media and telecoms
- Graduate of Cambridge University with a degree in Social and Political Sciences
Key Achievements
- ComplyAdvantage into a global RegTech leader serving major financial institutions
- MarketInvoice to become one of the UK's leading alternative finance platforms
- Recognized as a fintech thought leader and frequent speaker at industry conferences
- Angel investor in 180+ companies
Latest News
Domino’s Pizza Slides After Missing Comparable Sales Estimate
Domino’s Pizza Inc. shares slipped after the company reported a smaller-than-expected increase in comparable sales, citing growing competition and economic challenges.
Beer Stocks Set for Billion-Pint World Cup Boost, Jefferies Says
This summer’s soccer World Cup is expected to provide relief to the shares of European beer makers including Anheuser-Busch InBev SA and Heineken NV, according to analysts at Jefferies.
India’s Sun Pharma Plots $12 Billion Organon Buyout For Global Reach
Sun Pharmaceutical Industries Ltd. has agreed to acquire New York-listed women’s health-care company Organon & Co., expanding its global reach with one of the biggest outbound deals by an Indian...
US Stocks Hold Highs as Busy Earnings Week Starts: Markets Wrap
US stocks held near record highs at the start of a week that will feature a raft of megacap tech earnings and central bank decisions, with the Strait of Hormuz still shut after efforts to resume US-Ir...